Pharmacology has been a major field of clinical laboratory. Firstly in the
emergency measures for the diagnosis of possible poisoning, and secondly in the
monitoring of various treatments, mainly antibiotics and anticonvulsants, but also
others in such as antidepressants, digitalis, anxiolytics, etc.
The discovery of biological treatments, based on the use of monoclonal antibodies, and
their use for the treatment of various chronic diseases, whether the digestive tract or the
rheumatic diseases, is considered a big step in favor of patients and their quality of life.
However, these treatments have had a worse response than they were supposed to,
sometimes due to their own immunogenicity of these monoclonal antibodies in the
organism, triggering responses to the drug itself, which reduces their effectiveness and
also involves high costs and secondary effects to patients. That is why the biological
monitoring of drugs has been proven to be a way to improve treatment adherence, and
cost-effectiveness. In turn, it is also important to determine the presence of antibodies
generated by the patient in response to the drug, because these cases determine
inefficient and highly expensive treatments and the injury to the patient.
Keywords: ADA, Adalimumab, Ankylosing Spondylitis, Anti-TNF alpha
Therapy, Antibodies, Biologic Treatment, Chronic Inflammation, Etanercept,
HACA, Inflammatory Bowel Diseases, Infliximab, Monitoring, Monoclonal,
Pharmacodynamics, Pharmacokinetics, Pharmacology, Rheumatoid Arthritis,
TNF alpha.
